Abeona Therapeutics Inc. ABEO
2.60 USD +0.18 (+7.44%)
Regular-session close
2.62 +0.02 +0.77%
After hours · Nov 16, 4:00 PM ET
2.36 Day range 2.62
2.09 52-week range 7.65
- YTD
- -50.66%
- 1 year
- -41.57%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $18 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Abeona Therapeutics (NASDAQ:ABEO) with a Buy and lowers the price target from $20 to $18.
marketbeat.com Abeona Therapeutics Plans New Phase 3 Trial for ABO-801 as ZEVASKYN Launch Expands Abeona Therapeutics NASDAQ: ABEO plans to advance its newly acquired eosinophilic esophagitis drug candidate into another Phase 3 study while expanding the commercial launch of ZEVASKYN, executives…
globenewswire.com Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences CLEVELAND, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com Abeona Therapeutics Acquires Late-Stage Drug Candidate, Secures $30 Million in Equity Financing Abeona beats EPS estimates but misses revenue, acquires ABO-801, raises $30M, and reports growing ZEVASKYN sales and Medicare support.benzinga.com Abeona Therapeutics Acquires ABO-801, Product Candidate For EoE, From Ellodi Pharma, For $20M Equity Consideration; Enters Into Securities Purchase Agreement For $30M Private Placement Financing - Adds a once-daily, oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track Designations –– ABO-801 acquired for $20 million equity consideration at closing with no…
benzinga.com Abeona Therapeutics Q3 EPS $(0.08) Beats $(0.15) Estimate, Sales $13.491M Miss $16.484M Estimate Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.15) by 46.67 percent. This is a 20 percent increase over losses of…
